The new classification came into force Wednesday.
Epidyolex is the trade name in Europe for Epidiolex.
London-based GW Pharmaceuticals, the maker of Epidyolex, cheered the move. Among other things, the change extends the length of time for a valid prescription.
“The decision to move Epidyolex to a low level of control is an important one for patients, their families, health-care professionals, pharmacists and the (National Health Service) as a whole – reducing costs and ensuring the medicine can be dispensed more easily,” Chris Tovey, GW Pharma’s chief operating officer, said in a news release.
The U.K. allowed doctors to prescribe Epidyolex in 2018. A year later, the European Commission followed suit.
GW ended 2019 with $311.3 million in sales.
GW Pharma trades on the Nasdaq as GWPH.